Treatment of peptic ulcer disease in the arthritic patient.
Dyspepsia associated with arthritis and non-steroidal anti-inflammatory drugs (NSAIDs) is a common clinical problem. Up to 80% of deaths attributable to peptic ulceration may be associated with NSAID usage. The problem is foremost in the elderly population, in which there has been an increase both in the incidence of peptic ulcers and in the use of NSAIDs. Although the development of duodenal ulceration is not clearly associated with NSAIDs, it is accepted that these drugs increase the risk of gastric ulceration and the occurrence of peptic ulcer complications. Asymptomatic peptic ulceration is common, and patients taking NSAIDs are often asymptomatic prior to presentation with life-threatening complications. The key principle in management of this problem is prevention through careful selection of patients for NSAID use, adequate treatment of peptic ulceration and maintenance of remission. A variety of effective drugs are available for the treatment of peptic ulcers, including H2-receptor antagonists, pirenzepine, sucralfate and colloidal bismuth subcitrate. However, it is recognised that peptic ulceration is a chronic disease with a relapsing-remitting course, often with asymptomatic ulcer episodes. The knowledge that current ulcer-healing strategies do not significantly alter this natural history has lead to increasing efforts to prevent relapse with effective 'maintenance' therapy.
Nunes
D
D
Department of Clinical Medicine, Trinity College, Dublin, Ireland.
Kennedy
N P
NP
Weir
D G
DG
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D001168:Arthritis / Q000150:complications*; D006801:Humans; D010437:Peptic Ulcer / Q000139:chemically induced / Q000188:drug therapy*; D013256:Steroids / Q000009:adverse effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D013256:Steroids